Grifols SA (GIFLF)
12.72
0.00 (0.00%)
USD |
OTCM |
Nov 17, 16:00
Grifols Shareholders Equity (Quarterly) : 6.574B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 6.574B |
| June 30, 2026 | 6.341B |
| March 31, 2026 | 6.289B |
| December 31, 2025 | 6.191B |
| September 30, 2025 | 6.085B |
| June 30, 2025 | 6.068B |
| March 31, 2025 | 6.092B |
| December 31, 2024 | 6.093B |
| September 30, 2024 | 5.971B |
| June 30, 2024 | 5.994B |
| March 31, 2024 | 6.419B |
| December 31, 2023 | 5.930B |
| September 30, 2023 | 6.487B |
| June 30, 2023 | 6.395B |
| March 31, 2023 | 6.359B |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 6.374B |
| December 31, 2020 | 6.250B |
| September 30, 2020 | 6.270B |
| Date | Value |
|---|---|
| June 30, 2020 | 6.026B |
| March 31, 2020 | 6.083B |
| December 31, 2019 | 5.413B |
| September 30, 2019 | 5.202B |
| June 30, 2019 | 5.004B |
| March 31, 2019 | 4.942B |
| December 31, 2018 | 4.830B |
| September 30, 2018 | 4.814B |
| June 30, 2018 | 4.632B |
| March 31, 2018 | 4.557B |
| December 31, 2017 | 4.358B |
| September 30, 2017 | 4.235B |
| June 30, 2017 | 4.082B |
| March 31, 2017 | 4.075B |
| December 31, 2016 | 3.925B |
| September 30, 2016 | 3.965B |
| June 30, 2016 | 3.786B |
| March 31, 2016 | 3.752B |
| December 31, 2015 | 3.581B |
| September 30, 2015 | 3.570B |
| June 30, 2015 | 3.421B |
| March 31, 2015 | 3.363B |
| December 31, 2014 | 3.216B |
| September 30, 2014 | 3.201B |
| June 30, 2014 | 3.055B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Pharma Mar SA | 269.20M |
| Oryzon Genomics SA | 168.08M |
| Agenus, Inc. | -105.37M |
| Amgen, Inc. | 14.35B |
| Anika Therapeutics, Inc. | 137.58M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 23.04B |
| Total Liabilities (Quarterly) | 13.67B |
| Debt to Equity Ratio | 1.596 |
| Current Ratio | 2.329 |
| Net Debt Paydown Yield | 0.02% |